The recent results of apixaban in the CARAVAGGIO study in patients with cancer associated thrombosis, including patients with gastro-intestinal cancer with very high risk of gastro-intestinal bleeding, have triggered us to organize this webcast. Additionally we will discuss results of studies in different patient sets (non-cancer VTE and AF).
In this webcast, pertinent published data available on all DOACs versus comparators are presented by international key opinion leaders in the field of venous thromboembolism treatment and stroke prevention in atrial fibrillation. This webcast will give the audience insight into results of clinical trials as well as real world studies, emphasizing the clinical relevance of differences between DOACs, and how this may support in their choice of treatment.
Talks
- Treatment of VTE in patients with cancer
- Treatment and long-term secondary prevention of VTE
- Prevention of stroke in patients with AF
Experts
- Prof. dr. Giancarlo Agnelli, internist, University of Perugia, Italy
- Dr. Alexander Cohen, vascular physician and epidemiologist, Guy’s and St Thomas’ Hospital London, United Kingdom
- Prof. dr. Gregory Lip, cardiologist, University of Liverpool, UK and Aalborg University, Denmark
- Prof. dr. Menno Huisman, internist in cardiovascular medicine, LUMC Leiden, The Netherlands (moderator)
Date
This webcast will be broadcast on Tuesday the 25th of May 2021 from 20.30 PM to 22.00 PM. The webcast will be in English.
Accreditation
Accreditation has been requested at the NIV, MDL, NVALT, NVVC, KNMP-OA. General practitioners can use the 25% arrangement to gain accreditation.
Audience
This webcast is intended for cardiologists, internists, geriatric specialists, gastroenterologists, hematologists, pharmacists and general practitioners.
Free webcast
Participation in this webcast is free of charge.
Questions
If you have any questions, please send an email to nascholing@springer.com.
This webcast is sponsored by
432-NL-2100009 maart 2021
-
Privacy Statement
In het kader van GDPR leeft Springer de wet- en regelgeving na zoals deze wordt gesteld door deze wet. Voor deze nascholing geldt dat het een samenwerking betreft tussen Springer, Pfizer en Bristol-Myers Squibb en dat zij elk hun eigen doel en middelen bepalen in de verwerking van persoonsgegevens. Springer, Pfizer en Bristol-Myers Squibb zijn daarmee afzonderlijk verwerkingsverantwoordelijken. De privacyvoorwaarden die van toepassing zijn vindt u hier: Springer Healthcare, Pfizer & Bristol-Myers Squibb.